192 related articles for article (PubMed ID: 10229049)
1. Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newborns.
Lecoq I; Brouard J; Laroche D; Férec C; Travert G
Acta Paediatr; 1999 Mar; 88(3):338-41. PubMed ID: 10229049
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
[TBL] [Abstract][Full Text] [Related]
3. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
[TBL] [Abstract][Full Text] [Related]
4. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
[TBL] [Abstract][Full Text] [Related]
5. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
6. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.
Ranieri E; Ryall RG; Morris CP; Nelson PV; Carey WF; Pollard AC; Robertson EF
BMJ; 1991 May; 302(6787):1237-40. PubMed ID: 2043846
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels.
Massie RJ; Wilcken B; Van Asperen P; Dorney S; Gruca M; Wiley V; Gaskin K
J Pediatr; 2000 Aug; 137(2):214-20. PubMed ID: 10931414
[TBL] [Abstract][Full Text] [Related]
8. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
9. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
10. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.
Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF
BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280
[TBL] [Abstract][Full Text] [Related]
11. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
Ogino S; Flodman P; Wilson RB; Gold B; Grody WW
Genet Med; 2005; 7(5):317-27. PubMed ID: 15915083
[TBL] [Abstract][Full Text] [Related]
12. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
[TBL] [Abstract][Full Text] [Related]
14. Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up.
Narzi L; Ferraguti G; Stamato A; Narzi F; Valentini SB; Lelli A; Delaroche I; Lucarelli M; Strom R; Quattrucci S
Clin Genet; 2007 Jul; 72(1):39-46. PubMed ID: 17594398
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
Parad RB; Comeau AM
J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
[TBL] [Abstract][Full Text] [Related]
16. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
[TBL] [Abstract][Full Text] [Related]
17. Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis.
Farrell PM; Koscik RE
Pediatrics; 1996 Apr; 97(4):524-8. PubMed ID: 8632940
[TBL] [Abstract][Full Text] [Related]
18. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen.
Kloosterboer M; Hoffman G; Rock M; Gershan W; Laxova A; Li Z; Farrell PM
Pediatrics; 2009 Feb; 123(2):e338-46. PubMed ID: 19171585
[TBL] [Abstract][Full Text] [Related]
19. Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses.
Férec C; Verlingue C; Parent P; Morin JF; Codet JP; Rault G; Dagorne M; Lemoigne A; Journel H; Roussey M
Hum Genet; 1995 Nov; 96(5):542-8. PubMed ID: 8530001
[TBL] [Abstract][Full Text] [Related]
20. Genetic counselling after carrier detection by newborn screening when one parent carries DeltaF508 and the other R117H.
Curnow L; Savarirayan R; Massie J
Arch Dis Child; 2003 Oct; 88(10):886-8. PubMed ID: 14500307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
